AD BT 2802
Alternative Names: AD-BT-2802Latest Information Update: 12 Jul 2022
At a glance
- Originator BioArctic
- Class Antibodies; Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease
Most Recent Events
- 07 Jul 2022 Early research in Alzheimer's disease in Sweden (unspecified route) (BioArctic pipeline, July 2022)